- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07491952
Zoom 시스템을 이용한 연속 이중 흡인 기술로 뇌졸중 치료 (ADAPT 2 0)
뇌졸중 치료를 위한 Zoom 시스템과 함께하는 연속 이중 흡인 기술의 임상 평가 (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Pojai Phattanagosai
- 전화번호: 650-740-7703
- 이메일: pphattanagosai@Imperativecare.com
연구 연락처 백업
- 이름: Emma Pham
- 전화번호: 408-421-7684
- 이메일: epham@imperativecare.com
연구 장소
-
-
Alabama
-
Huntsville, Alabama, 미국, 35801
- 모병
- Huntsville Hospital
-
연락하다:
- Farrar Hickey
-
수석 연구원:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, 미국, 94598
- 모병
- John Muir Health
-
수석 연구원:
- Benjamin Yim, MD
-
연락하다:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, 미국, 33606
- 모병
- University of South Florida
-
수석 연구원:
- Maxim Mokin, MD
-
연락하다:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, 미국, 30060
- 모병
- Wellstar Kennestone Hospital
-
연락하다:
- Autumn Lee
-
수석 연구원:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, 미국, 70503
- 모병
- Ochsner Clinic Foundation (Lafayette)
-
수석 연구원:
- Shail Thanki, MD
-
New Orleans, Louisiana, 미국, 70121
- 모병
- Ochsner Clinic Foundation
-
수석 연구원:
- James Milburn, MD
-
연락하다:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- 모병
- University of Maryland
-
수석 연구원:
- Jacob Cherian, MD
-
연락하다:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55407
- 모병
- Allina Health
-
연락하다:
- Emeryth Beloy
-
수석 연구원:
- Collin Torok, MD
-
-
New York
-
Albany, New York, 미국, 12208
- 모병
- Albany Medical College
-
수석 연구원:
- Alexandra Paul, MD
-
연락하다:
- Chelsey Large
-
Buffalo, New York, 미국, 14203
- 모병
- University at Buffalo Neurosurgery
-
수석 연구원:
- Jason Davies, MD
-
연락하다:
- Ellen Carl
-
New York, New York, 미국, 10065
- 모병
- Weill Cornell Medicine
-
연락하다:
- Hanah Hwang
-
수석 연구원:
- Amol Mehta, MD
-
New York, New York, 미국, 10029
- 모병
- Icahn School of Medicine at Mount Sinai
-
연락하다:
- Kevin Buttet
-
수석 연구원:
- Michael T Caton, MD
-
Syracuse, New York, 미국, 13210
- 모병
- SUNY Upstate Medical Center
-
연락하다:
- Saptarshi Prachi
-
수석 연구원:
- Haydn Hoffman, MD
-
The Bronx, New York, 미국, 10467
- 모병
- Montefiore Medical Center
-
연락하다:
- Genesis Liriano
-
수석 연구원:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45220
- 모병
- TriHealth Good Samaritan Hospital
-
수석 연구원:
- Andrew Ringer, MD
-
연락하다:
- Mehnaaz Ali
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma, Health Science Center
-
수석 연구원:
- Hakeem Shakir, MD
-
연락하다:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29605
- 모병
- Prisma Health - Upstate
-
연락하다:
- Shawn Manos
-
수석 연구원:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37902
- 모병
- Fort Sanders Regional Medical Center
-
연락하다:
- Cameron Carter
-
수석 연구원:
- Robert Hixson, MD
-
Memphis, Tennessee, 미국, 38120
- 모병
- Semmes Murphey Foundation
-
수석 연구원:
- Lucas Elijovich, MD
-
연락하다:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, 미국, 77339
- 모병
- HCA Houston Healthcare Kingwood
-
수석 연구원:
- Mohamad Ezzeldin, MD
-
연락하다:
- Swathi Potla
-
San Antonio, Texas, 미국, 78229
- 모병
- Methodist Healthcare System of San Antonio
-
연락하다:
- Samantha Franklin
-
수석 연구원:
- Lee Birnbaum, MD
-
San Antonio, Texas, 미국, 78229
- 모병
- University of Texas Science Health Center at San Antonio
-
수석 연구원:
- Justin Mascitelli, MD
-
연락하다:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- 모병
- University of Utah
-
연락하다:
- Andrew Grandemange
-
수석 연구원:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, 미국, 22042
- 모병
- Inova Fairfax Medical Campus
-
연락하다:
- Lauren Monroe
-
수석 연구원:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, 미국, 99204
- 모병
- Providence Sacred Heart Medical Center and Children's Hospital
-
연락하다:
- Kyle Kramer
-
수석 연구원:
- Christopher Zylak, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
설명
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
기간: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
기간: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
기간: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
기간: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
기간: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
기간: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
기간: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
기간: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
기간: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
기간: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
기간: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
공동 작업자 및 조사자
수사관
- 수석 연구원: David Fiorella, MD, Stony Brook University Hospital
- 수석 연구원: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- 수석 연구원: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- 수석 연구원: Maxim Mokin, MD, University of South Florida
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ICI-2025-003
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .